Improved Immunogenicity of HIV-1 Epitopes in HBsAg Chimeric DNA Vaccine Plasmids by Structural Mutations of HBsAg

Bryder, Karin; Sbai, Hakima; Nielsen, Henrik V.; Corbet, Sylvie; Nielsen, Claus; Whalen, Robert G.; Fomsgaard, Anders
March 1999
DNA & Cell Biology;Mar1999, Vol. 18 Issue 3, p219
Academic Journal
To improve the immunogenicity of epitopes from the envelope protein of HIV-1, we have developed gene gun-delivered subunit DNA vaccines by inserting the sequences encoding the V3 region into the hepatitis B virus (HBV) envelope gene, often called the surface antigen (HBsAg). We have examined the possibility of modifying the immune response to V3 by introducing modifications into the carrier HBsAg in gene gun DNA immunization of mice. In some plasmid constructions, the V3 sequence was introduced into the preS2 region of the HBsAg. Although this region is not present in all protein subunits of the HBsAg particles produced, abolishing the internal translational initiation site for the S protein had no effect on the immune response to V3. Expression of V3 at the N-terminal or C-terminal part of the HBsAg protein resulted in equal anti-V3 antibody and cytotoxic T-lymphocyte (CTL) responses. However, elimination of secretion by single amino-acid mutations in the HBsAg decreased the anti-HBsAg antibody response but enhanced the anti-V3 antibody response. In contrast, the CTL response to V3 was independent of the structural mutations but could be improved by a total deletion of the HBsAg sequence part. Thus, the immune response to heterologous epitopes can be altered by modifications in the carrier HBsAg protein. Modifications of the HBsAg carrier might interfere with the dominant immune response to the HBsAg epitopes, allowing better antibody induction to less immunogenic foreign epitopes. However, for induction of CTL responses, the expression of minimal epitopes may be advantageous.


Related Articles

  • Immunogenicity of enhanced green fluorescent protein (EGFP) in BALB/c mice: identification of an H2-Kd-restricted CTL epitope. Gambotto, A; Dworacki, G; Cicinnati, V; Kenniston, T; Steitz, J; Tüting, T; Robbins, P D; DeLeo, A B // Gene Therapy;Dec2000, Vol. 7 Issue 23, p2036 

    Enhanced green fluorescent protein (EGFP) is a novel marker gene product, which is readily detectable using techniques of fluorescence microscopy, flow cytometry, or macroscopic imaging. In the present studies, we have examined the immunogenicity of EGFP in murine models. A stable transfectant...

  • Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine. Kim, Jong J; Trivedi, Neil N; Wilson, Darren M; Mahalingam, Sundarasamy; Morrison, Lake; Tsai, Anthony; Chattergoon, Michael A; Dang, Kesen; Patel, Mamata; Ahn, Lois; Boyer, Jean D; Chalian, Ara A; Shoemaker, Hubert; Kieber-Emmons, Thomas; Agadjanyan, Michael A; Weiner, David B // Oncogene;12/17/98, Vol. 17 Issue 24, p3125 

    Nucleic acid immunization has been investigated as immunotherapy for infectious diseases as well as for treating specific types of cancers. In this approach, nucleic acid expression cassettes are directly inoculated into the host, whose transfected cells become the production source of novel and...

  • Experimental Molecular Design of Combined Vaccines. Lebedev, L. R.; Goncharova, E. P.; Sizov, A. A.; Bulychev, L. E.; Odegov, A. M.; Ryzhikov, A. B. // Molecular Biology;May/Jun2003, Vol. 37 Issue 3, p464 

    A method was elaborated to construct combined artificial immunogens simulating virus particles. The gist was exposing protein antigenic determinants of one virus on the particle surface and delivering plasmids with genes for antigenic proteins of another virus to specialized immune cells. Such...

  • Clustered epitopes within a new poly-epitopic HIV-1 DNA vaccine shows immunogenicity in BALB/c mice. Jafarpour, Nazli; Memarnejadian, Arash; Aghasadeghi, Mohammad; Kohram, Fatemeh; Aghababa, Haniyeh; Khoramabadi, Nima; Mahdavi, Mehdi // Molecular Biology Reports;Aug2014, Vol. 41 Issue 8, p5207 

    Despite a huge number of studies towards vaccine development against human immunodeficiency virus-1, no effective vaccine has been approved yet. Thus, new vaccines should be provided with new formulations. Herein, a new DNA vaccine candidate encoding conserved and immunogenic epitopes from HIV-1...

  • The Average IFN-γ Secreting Capacity of Specific CD8+ TCells Is CompromisedWhile Increasing Copies of a Single T Cell Epitope Encoded by DNA Vaccine. Yanmin Wan; Jing Wang; Haizhu Zhou; Zhidong Hu; Xiaonan Ren; Jianqing Xu // Clinical & Developmental Immunology;2012, p1 

    Previous studies suggested that both the frequency and the mean fluorescence intensity (MFI) of cytokine secreting T cells could be of great value for immunogenicity evaluation of a vaccine. In this study, by constructing epitope-based DNA vaccines encoding a previously identified CD8+ T cell...

  • Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis. Selenica, Maj-Linda B.; Davtyan, Hayk; Housley, Steven B.; Blair, Laura J.; Gillies, Anne; Nordhues, Bryce A.; Bo Zhang; Liu, Joseph; Gestwicki, Jason E.; Lee, Daniel C.; Gordon, Marcia N.; Morgan, Dave; Dickey, Chad A. // Journal of Neuroinflammation;2014, Vol. 11 Issue 1, p1 

    Background Abnormal tau hyperphosphorylation and its accumulation into intra-neuronal neurofibrillary tangles are linked to neurodegeneration in Alzheimer's disease and similar tauopathies. One strategy to reduce accumulation is through immunization, but the most immunogenic tau epitopes have so...

  • Encapsulation into sterically stabilised liposomes enhances the immunogenicity of melanoma-associated Melan-A/MART-1 epitopes. Adamina, M.; Bolli, M.; Albo, F.; Cavazza, A.; Zajac, P.; Padovan, E.; Schumacher, R.; Reschner, A.; Feder, C.; Marti, W.R.; Oertli, D.; Heberer, M.; Spagnoli, G.C. // British Journal of Cancer;1/12/2004, Vol. 90 Issue 1, p263 

    Tumour-associated antigens (TAA)-specific vaccination requires highly immunogenic reagents capable of inducing cytotoxic T cells (CTL). Soluble peptides are currently used in clinical applications despite an acknowledged poor immunogenicity. Encapsulation into liposomes has been suggested to...

  • A high-performance thioredoxin-based scaffold for peptide immunogen construction: proof-of-concept testing with a human papillomavirus epitope. Canali, Elena; Bolchi, Angelo; Spagnoli, Gloria; Seitz, Hanna; Rubio, Ivonne; Pertinhez, Thelma A.; Müller, Martin; Ottonello, Simone // Scientific Reports;4/25/2014, p1 

    Escherichia coli thioredoxin has been previously exploited as a scaffold for the presentation/stabilization of peptide aptamers as well as to confer immunogenicity to peptide epitopes. Here we focused on other key features of thioredoxin that are of general interest for the production of safer...

  • Immunogenicity of a Promiscuous T Cell Epitope Peptide Based Conjugate Vaccine against Benzo[a]pyrene: Redirecting Antibodies to the Hapten. Schellenberger, Mario T.; Grova, Nathalie; Farinelle, Sophie; Willième, Stéphanie; Revets, Dominique; Muller, Claude P. // PLoS ONE;May2012, Vol. 7 Issue 5, p1 

    The prototype polycyclic aromatic hydrocarbon benzo[a]pyrene (B[a]P) is an environmental pollutant and food contaminant of epidemiological importance. To protect against adverse effects of this ubiquitous carcinogen, we developed an immunoprophylactic strategy based on a B[a]P-protein conjugate...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics